Pharma Predictions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Predictions

Pharmaceutical Technology



Ahead in active pharmaceutical ingredients: "The opportunities lie" in biologics-based drug candidates, and "the innovation is in" emerging or small- to medium-sized pharmaceutical companies.

Ahead in analytical technology: "[Supercritical fluid chromatography] is maturing for analytical and preparatory chromatography."

Ahead in outsourcing: Readers felt that outsourcing, including "mergers," "India and China," and "clinical/biological testing outsourcing," would have a major impact on industry as it allows for "cheaper" costs, "increased flexibility," and "more independent firms." Others felt outsourcing was leading to a "shutdown of Big Pharma manufacturing sites," and job loss.


Photo Credit: Photos.com
Ahead in dosage forms: "The [technique] of developing a solid dosage from a liquid version, even though it is very advanced, is still in its beginning stages."

Ahead in manufacturing: "We hope the [Critical Path Initiative] will speed up approval times." "Pharmaceutical companies need to keep their investigation of new drugs to compensate for the competition of generic drugs." "ICH [International Conference on Harmonization] is now the benchmark for determining regulatory requirements." "The formation of the EP [European Pharmacopoeia] is leveling, but has not leveled, the playing field." And, said another participant, "[The EP] will help the harmonization process... [and] facilitate global drug development markedly."

Ahead in compression technologies: "We are definitely seeing the desire for using APIs [active pharmaceutical ingredients] in combination [for bi- and tri-layered tablets.]"

Ahead in containment: "...There is more awareness of extracting, leaching, and cleaning residues contamination. There appears to be a drive to do real-time surfaces analysis."

Ahead in analytical testing: "More advanced water testing instruments are gaining acceptance in pharmaceutical laboratories."

Ahead in process development: "Green chemistry is openly challenging the best minds to look for greener alternatives to current chemical issues."

See the July 2007 issue for more coverage of the 30th Anniversary Survey.

Your opinion matters.

To contribute to this column, send your proposal to
.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here